Patterns of genetic alterations could guide management.
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Background: Cachexia affects nearly 50–80% of cancer patients, and most studies have only focused on elderly patients. We investigated preoperative cachexia in gastric cancer (GC) patients by age group and comprehensively analyzed the impact of preoperative cachexia on the prognosis of GC patients in all age groups.Methods: In total, 575 patients were prospectively analyzed. The effect of…
Ten different drugs continued to kill cancer cells even when their target proteins were removed.